Obesity is a chronic disease characterized by excessive body fat that increases the risk of various health conditions. According to the World Health Organization, in 2022, more than 1 billion people worldwide were living with obesity, accounting for a significant global health burden. With rising prevalence, there is a growing focus on developing better therapies and innovative obesity drug candidates. Advances in obesity therapeutics, including novel mechanisms targeting appetite regulation and metabolism, are driving growth in the market. Increased research investments, regulatory support, and the demand for effective treatments are expected to accelerate the development of obesity therapeutic products in the coming years.
Major companies involved in the obesity pipeline drugs market include Pfizer, Eli Lilly and Company, and others.
Leading drugs currently in the pipeline include IBI362, and Petrelintide, among others.
Rising global obesity rates, increased investment in novel therapeutics, and advancements in GLP-1 receptor agonists and combination therapies are driving growth in the obesity drug pipeline.
The Obesity Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into obesity therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for obesity. The obesity report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The obesity pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with obesity treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to obesity.
Obesity is a complex chronic disease characterized by excessive body fat accumulation. It typically occurs due to an imbalance between calorie intake and energy expenditure, influenced by genetics, sedentary behavior, poor nutrition, and hormonal imbalances. Environmental factors and psychological stress may also contribute. This condition increases the risk of various health complications, including heart disease, type 2 diabetes, and certain cancers.
Obesity treatment approaches include lifestyle modifications, medical interventions, and surgical options. It begins with a personalized plan focusing on balanced nutrition, regular physical activity, and behavioral therapy. Healthcare providers may prescribe medications to regulate appetite or metabolic function. In severe cases, bariatric surgery may be recommended to facilitate significant weight loss and improve overall health outcomes.
The global obesity epidemic continues to rise. A 2022 published in The Lancet reported over 1 billion people living with obesity. In 2023, CDC data showed obesity rates exceeding 35% in 23 states of the United States. In England (2023–24), childhood obesity rates increased slightly in younger children but declined in older ones. India had 70 million obese adults in 2022, while Japan’s male obesity rate stood at 31.5% in 2023.
This section of the report covers the analysis of obesity drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total obesity clinical trials.
The drug molecule categories covered under the obesity pipeline analysis include small molecules, monoclonal antibodies, RNA-based therapies, gene therapies, and others. The obesity report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for obesity.
The EMR report for the obesity drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed obesity therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in obesity clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for obesity. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of obesity drug candidates.
IBI362 being developed by Innovent Biologics (Suzhou) Co. Ltd., is undergoing a Phase III clinical trial to assess its efficacy and safety in adults with obesity. It is a long-acting synthetic peptide analogue targeting GLP-1 and glucagon receptors, enhancing glucose control and promoting significant weight loss. The study, involving approximately 462 participants, is expected to conclude by September 2025.
Petrelintide, backed by Zealand Pharma, is an investigational long-acting amylin analogue developed for obesity and overweight patients with weight-related comorbidities. Administered once weekly via subcutaneous injection, Petrelintide enhances satiety by working on amylin receptors and restoring leptin sensitivity, distinguishing it from GLP-1 receptor agonists. This Phase II trial is evaluating its effect on body weight, safety, and tolerability.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Obesity Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for obesity. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into obesity collaborations, regulatory environments, and potential growth opportunities.
Obesity Market Report and Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share